

Identifying markers of successful dose reduction in the maintenance phase of tofacitinib treatment of ulcerative colitis

Submission date 09/08/2021	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 07/09/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 20/11/2024	Condition category Digestive System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Tofacitinib is an orally administered drug that has been shown to be effective in patients with moderate to severe ulcerative colitis (UC), an incurable, chronic inflammatory condition of the large bowel. The tofacitinib clinical trials demonstrate that the 10mg twice daily maintenance dose is superior to the 5mg twice daily dose in those with prior treatment failure for UC. Accordingly, many practitioners favour continuing the 10mg twice daily dose in higher-risk patients with prior treatment-resistant disease, rather than dropping to the 5mg twice daily maintenance dose at week 8 (or week 16 in those slower to respond).

This dosing decision needs to be balanced against the potential risk of continuing at the higher dose; there is a higher risk of side effects such as infection and blood clots with the 10mg twice daily dose.

Given that most patients who are receiving tofacitinib are treatment resistant, there is an urgent need to identify ways to predict which patients are more likely to flare should their dose reduce. Such biomarkers would enable us to risk stratify our patients at the point of consideration of dose reduction, to enable assessment of the risk and benefit of dose reduction versus continuation at the higher dose.

This study aims to explore clinical and laboratory-based markers (from blood and colon tissue), which in turn may help make key treatment decisions for tofacitinib-treated patients. We hypothesise that patients who relapse following dose reduction will have changes in cytokine expression of their pro-inflammatory T cells in peripheral blood mononuclear cells (PBMCs), increased STAT activation in PBMCs, and possibly signature genes in their colonic tissue.

Who can participate?

Adults aged 18 years or above with a history of ulcerative colitis, as defined by standard clinical criteria and who are having their tofacitinib dose reduced from 10mg BD to 5mg BD in view of an adequate response, as decided by their treating clinical team, and are undergoing routine endoscopy.

What does the study involve?

Participants will go ahead with participants flexible sigmoidoscopy (camera test) as planned. The endoscopist will take a series of 12 extra biopsies for this study in addition to 2-4 standard biopsies. The biopsy samples will be used for two purposes; 1, to make another assessment of how active participants' colitis is and 2, to carry out scientific analysis to identify genes that may act as predictors of relapse. This analysis aims to study RNA (a photocopy of the DNA), which acts as a messenger and can give important clues about the processes that occur within the bowel during disease relapse.

Immediately following the procedure, in addition to standard baseline blood tests we will also take an additional vial of blood for this study (approximately 5 teaspoons). This will be to allow us to perform analyses looking for inflammatory messengers and markers that may predict relapse.

Should participants undergo another flexible sigmoidoscopy if participants were to relapse, and after 44 weeks of dose reduction as is standard, the study biopsies and blood tests will be repeated in addition to standard tests. Otherwise, participants will be managed by the participants treating team in the standard way. Participants' participation in the study will end if the relapse means that participants need to stop tofacitinib and commence a different drug, or if the relapse means that participants require surgery to remove the large bowel. Participating in this study will not affect how participants are treated. We will monitor participants' progress and collect participants' data that will come from participants' standard investigations and management.

What are the possible benefits and risks of participating?

Although there are no direct benefits to the patient by taking part, the results and analyses from this study may help other patients who have ulcerative colitis and are being treated with tofacitinib.

Where is the study run from?

Guy's and St Thomas' NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

August 2019 to October 2023

Who is funding the study?

Pfizer (UK)

Who is the main contact?

Dr Sailish Honap, shonap@nhs.net

Contact information

Type(s)

Public

Contact name

Dr Sailish Honap

ORCID ID

<https://orcid.org/0000-0001-6657-2763>

Contact details

Department of Gastroenterology
St Thomas' Hospital
Westminster Bridge Road
Lambeth
London
United Kingdom
SE1 7EH
+44 (0)207 1882499
shonap@nhs.net

Type(s)

Scientific

Contact name

Dr Peter Irving

ORCID ID

<https://orcid.org/0000-0003-0972-8148>

Contact details

Department of Gastroenterology
St Thomas' Hospital
Westminster Bridge Road
Lambeth
London
United Kingdom
SE1 7EH
+44 (0)2071882499
peter.irving@gstt.nhs.uk

Type(s)

Scientific

Contact name

Dr Susan John

ORCID ID

<https://orcid.org/0000-0002-5620-1982>

Contact details

Department of Immunobiology
Floor 2, Borough Wing
Guy's Hospital
St Thomas' Street
London
United Kingdom
SE1 9RT
+44 (0)2071889614
susan.john@kcl.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

276727

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

IRAS 276727, CPMS 49789

Study information

Scientific Title

Biomarkers of Relapse In ulcerative colitis patients after Tofacitinib dose rEduction (BRITE)

Acronym

BRITE

Study objectives

We hypothesise that patients who relapse following maintenance dose reduction of tofacitinib will have increased markers of pro-inflammatory effector T cells in peripheral blood and inflamed mucosal tissue. The principal questions we aim to address are as follows;

1. Is there increased activation of STAT proteins in peripheral blood in patients who relapse?
2. Are there changes in cytokine expression in peripheral T cells that predict relapse?
3. Can we identify signature gene(s) that serve as a biomarker to predict relapse?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 11/08/2021, Yorkshire & The Humber - Leeds East Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8018; leedseast.rec@hra.nhs.uk), ref: 21/YH/0148

Study design

Prospective multi-centre observational study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

See additional files

Health condition(s) or problem(s) studied

Adult patients in the maintenance phase of tofacitinib treatment of ulcerative colitis

Interventions

This is a prospective, observational, investigator-initiated study with an overarching objective to identify biochemical and genetic markers of patients more likely to flare after tofacitinib dose reduction. This will eventually allow us to target continued higher dosing of 10mg bd at those patients who are most likely to benefit from it and avoid its use in patients in whom it is potentially unnecessary. Thereby, it would enable using the drug in a safer, more effective, and more economical manner.

We will prospectively enrol a cohort of 50 UC patients who have achieved an adequate response to tofacitinib at a dose of 10mg bd and whose dose is being reduced to 5mg bd. Post-induction flexible sigmoidoscopy will be performed as part of routine clinical care and colonic tissue and blood samples will be collected at study entry. Patients' disease course will be followed-up through routine care to the point of flare, or week 44 post-induction.

Briefly, to address the study questions above, we will firstly monitor the phosphorylation of STAT proteins in peripheral blood mononuclear cells from patients enrolled in the study, with blood drawn before dose reduction and at the point of flare. Secondly, we will evaluate cytokine expression in peripheral CD4 T cells to see if there are any changes that predict relapse. Finally, we will compare gene expression profiles from colonic tissue of patients who remain symptomless on the lower dose of tofacitinib with those patients who ultimately show clear clinical signs of relapse.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Tofacitinib

Primary outcome measure

At week 44 and at relapse (if applicable):

1. Clinical status (simple clinical colitis activity index and partial Mayo score)
2. C-reactive protein and faecal calprotectin
3. Histological markers of disease activity (Nancy histological index)
4. STAT activation in peripheral blood mononuclear cells
5. Cytokine expression in peripheral T cells
6. Gene signatures in colonic biopsies

Secondary outcome measures

There are no secondary outcome measures

Overall study start date

23/08/2019

Completion date

31/10/2023

Eligibility

Key inclusion criteria

1. Aged 18 years or over, either male or female
2. A history of ulcerative colitis, as defined by standard clinical criteria
3. Patients who are having their tofacitinib dose reduced from 10mg BD to 5mg BD in view of adequate response, as decided by their treating clinical team, and are undergoing routine endoscopy.
4. Sufficient English language skills to understand the patient information sheet and consent form.

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

50

Total final enrolment

50

Key exclusion criteria

1. Patients undergoing dose reduction for reasons other than adequate response to 10mg bd (ie. active infection or VTE risk).
2. Patients being dose reduced without undergoing endoscopy
3. Patients with insufficient English language skills to understand the patient information sheet and consent form.

Date of first enrolment

10/09/2021

Date of final enrolment

01/09/2022

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

St Thomas' Hospital

IBD Centre

Department of Gastroenterology

1st Floor College House

South Wing

London

United Kingdom

SE1 7EH

Sponsor information

Organisation

Guy's and St Thomas' NHS Foundation Trust

Sponsor details

R&D Department

16th Floor, Tower Wing

Great Maze Pond

Guy's Hospital

London

England

United Kingdom

SE1 9RT

+44 (0)2071889811

R&D@gstt.nhs.uk

Sponsor type

Hospital/treatment centre

Website

<https://www.guysandstthomas.nhs.uk/Home.aspx>

ROR

<https://ror.org/00j161312>

Organisation

King's College London

Sponsor details

Room 5.31

James Clerk Maxwell Building

57 Waterloo Road

London

England

United Kingdom

SE1 8WA

+44 (0)207 8483224

reza.razavi@kcl.ac.uk

Sponsor type

University/education

Website

<https://www.kcl.ac.uk/>

ROR

<https://ror.org/0220mzb33>

Funder(s)**Funder type**

Industry

Funder Name

Pfizer

Alternative Name(s)

Pfizer Inc., Pfizer Consumer Healthcare, Davis, Charles Pfizer & Company, Warner-Lambert, King Pharmaceuticals, Wyeth Pharmaceuticals, Seagen

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal. Data presented and published will be in an aggregated/summarised form and will not be available at participant level.

Intention to publish date

01/09/2025

Individual participant data (IPD) sharing plan

All data generated or analysed during this study will be included in the subsequent results publication.

IPD sharing plan summary

Other

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	version 2.0	03/08/2021	11/08/2021	No	Yes
Protocol file	version 1.0	07/06/2021	13/08/2021	No	No
HRA research summary			20/09/2023	No	No